natgillin/translations-raw huggingface dataset:
Nine out of 56 patients were persistently positive (anti-vedolizumab antibody-positive at two or more study visits) and 33 patients developed neutralizing anti-vedolizumab antibodies.
Devet od 56 bolesnika bili su trajno pozitivni (anti-vedolizumab protutijela pozitivni u dva ili više posjeta tijekom ispitivanja), a 33 bolesnika razvila su neutralizirajuća anti-vedolizumab protutijela.
Nine patients treated with ofatumumab and chlorambucil, and three patients treated with chlorambucil alone had late onset neutropenia, defined as Grade 3 or 4 neutropenia starting at least 42 days after the last treatment.
U devet bolesnika liječenih ofatumumabom i klorambucilom i tri bolesnika liječena samo klorambucilom primijećena je odgođena neutropenija, koja se definira kao neutropenija 3. ili 4. stupnja koja nastupa najmanje 42 dana nakon posljednje doze.
Nine pre-specified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non-infectious pulmonary complications, and death).
Procjenjivano je devet unaprijed definiranih kategorija štetnih događaja (kardiovaskularni tromboembolijski događaji, perikarditis, novonastalo kongestivno zatajenje srca ili pogoršanje postojećeg, zatajenje/poremećaj funkcije bubrega, komplikacije ulkusa gornjeg gastrointestinalnog trakta, velika krvarenja izvan gastrointestinalnog sustava, infekcije, neinfektivne plućne komplikacije i smrt).
Nine weeks after exposure, this effect was no longer observable.
Devet tjedana nakon izlaganja taj se učinak više nije mogao opaziti.
Nine years after vaccination, 94%, 96%, 99% and 60% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 98%, 96%, 100% and 91% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
Devet godina nakon cijepljenja, 94% bilo je seropozitivno na tip 6 HPV-a, 96% na tip 11; 99% na tip 16 i 60% na tip 18, na temelju nalaza cLIA testa, a na temelju nalaza IgG LIA testa 98% bilo je seropozitivno na tip 6 HPV-a, 96% na tip 11; 100% na tip 16 i 91% na tip 18.
Nine- day-old broilers from the group of chicks vaccinated at one-day-old were challenged with MD virus and 82% of the chickens were protected compared with 12% in the unvaccinated group.
Devet dana stari brojleri iz grupe pilića cijepljenih u starosti od jednog dana bilo je izazvano virusom MD-a, te je 82% pilića bilo zaštićeno u usporedbi s 12% onih u necijepljenoj grupi.
Nine-day- old broilers from the chicks vaccinated at one-day-old were challenged with MD virus and Vectormune ND provided protection to 90% of the chickens compared with 9-12% in the unvaccinated group.
Devet dana stari brojler pilići cijepljeni u starosti od jednog dana izazvani su virusom MD-a, te je Vectormune ND pružio zaštitu do 90% pilića u usporedbi s 9-12% onih u necijepljenoj grupi.
Nine-day-old broilers from vaccinated eggs were challenged with MD virus and 85% of the chickens were protected compared with 9% in the unvaccinated group.
Devet dana stari brojleri iz cijepljenih jaja izazvani su virusom MD-a, te je 85% pilića bilo zaštićeno u usporedbi s 9% onih u necijepljenoj grupi.
Nine-day-old chickens from vaccinated eggs were challenged with MD virus and 88% of the chickens were protected compared with 9-12% in the unvaccinated group.
Devet dana stari pilići iz cijepljenih jaja bili su izazvani MD virusom dok je 88% pilića bilo zaštićeno u usporedbi s 9-12 % onih u necijepljenoj grupi.
Nineteen (19) of the cases of localised pallor were not associated with any other adverse events; only 5 out of these 19 patients discontinued treatment as a result of the pallor.
Devetnaest (19) slučajeva lokaliziranog bljedila nisu bili povezani s nijednim drugim štetnim događajima; od ovih 19 bolesnika, samo 5 je prekinulo liječenje zbog bljedila.
Ninety nine patients were treated with MabThera and 12% experienced at least one IRR.
Devedeset i devet je bolesnika liječeno lijekom MabThera i 12% ih je imalo barem jednu reakciju povezanu s infuzijom.
Ninety one percent of patients had a baseline ECOG performance status of 0 or 1 and 9% had an ECOG performance status of 2.
Devedest i jedan posto bolesnika imalo je na početku ECOG funkcionalni status 0 ili 1, a 9% bolesnika imalo je ECOG funkcionalni status 2.
Ninety patients randomised to placebo + BR crossed over to receive IMBRUVICA following IRC confirmed progression.
Devedeset bolesnika randomiziranih na placebo + BR prešlo je na uzimanje lijeka IMBRUVICA nakon što je nezavisno IRC potvrdio progresiju.
Ninety seven (97) patients in the IFN alfa-2a arm and 131 patients in the Avastin arm reduced the dose of IFN alfa-2a from 9 MIU to either 6 or 3 MIU three times a week as pre-specified in the protocol.
U 97 bolesnika koji su primali IFN alfa-2a i 131 bolesnika koji je primao Avastin doza interferona alfa-2a smanjena je sa 9 milijuna IU na 6 ili 3 milijuna IU tri puta tjedno, kako je prethodno utvrđeno u protokolu ispitivanja.
Ninety-eight (98) of the original 110 patients continued treatment in a second supportive study and had subsequent extended exposure to ReFacto AF with a median of 169 additional ED (range 9-425).
Devedeset osam (98) od prvobitnih 110 bolesnika nastavilo je liječenje u drugom potpornom ispitivanju i imalo je produženu izloženost lijeku ReFacto AF s medijanom od 169 dodatnih ED (raspon 9-425).
Ninety-eight percent (98 %) of subjects received prior doxorubicin, 70 % prior ifosfamide, and 65 % of subjects had received at least three or more chemotherapeutic agents prior to study enrolment.
Devedeset i osam posto (98%) bolesnika prethodno je primilo doksorubicin, 70% ifosfamid, a njih 65% primilo je najmanje tri ili više kemoterapijskih lijekova prije uključenja u ispitivanje.
Ninety-eight percent of all subjects receiving palivizumab completed the study and 97% received all five injections.
98% ispitanika koji su dobivali palivizumab je završilo ispitivanje, dok je 97% dobilo svih pet injekcija.
Ninety-eight percent of dogs returned to normal plasma testosterone levels within 18 months of implantation.
98% pasa vratilo je normalne vrijednosti testosterona u 18 mjeseci od implantacije.
Ninety-five percent (225/237) of patients without cirrhosis at baseline and 99% (93/94) of patients with cirrhosis at baseline had either no change or an improvement in fibrosis (Ishak fibrosis score).
95% (225/237) pacijenata bez ciroze na početku i 99% (93/94) pacijenata s cirozom na početku nisu imali nikakve promjene fibroze niti poboljšanje fibroze (Ishakova ljestvica fibroze).
Ninety-seven patients were enrolled at various doses and schedules; 55 patients received 50 mg at the recommended treatment schedule 4 weeks on /2 weeks off (“schedule 4/2”).
U ispitivanje je uključeno 97 bolesnika koji su primali različite doze i sheme doziranja; 55 bolesnika je primalo dozu od 50 mg prema preporučenoj shemi liječenja: 4 tjedna primjene lijeka/2 tjedna bez lijeka („shema 4/2“).
Ninety-seven percent of all subjects receiving palivizumab completed the study and 95% received all five injections.
97% ispitanika koji su dobivali palivizumab je završilo ispitivanje, dok je 95% dobilo svih pet injekcija.
Ninety-seven percent of patients (37 out of 39 patients treated with teduglutide) that completed the placebo-controlled study entered a long-term extension study where all patients received 0.05 mg/kg of Revestive daily for up to an additional 2 years.
Devedeset sedam posto bolesnika (37 od 39 bolesnika liječenih teduglutidom) koji su završili placebom kontrolirano ispitivanje uključeno je u dugotrajni produžetak ispitivanja u kojem su svi bolesnici primali 0,05 mg/kg lijeka Revestive dnevno tijekom dodatne 2 godine.
Ninety-seven percent of the patients who completed the randomised trials in patients with partial onset seizures were enrolled in the open label extension study (n=1186).
Devedeset i sedam posto bolesnika koji su završili randomizirana ispitivanja u bolesnika s parcijalnim napadajima bilo je uključeno u otvoreni produžetak ispitivanja (n=1186).
Ninety-six percent of patients on dabrafenib monotherapy in the integrated safety population and all patients on combination therapy in the Phase III studies who developed cuSCC continued on treatment without dose modification.
Devedeset i šest posto bolesnika na monoterapiji dabrafenibom u integriranoj populaciji u kojoj se ispitivala sigurnost i svi bolesnici na kombiniranoj terapiji u ispitivanjima faze III u kojih se razvio cuSCC nastavilo je primati terapiju bez prilagodbe doze.
Ninety-three percent and 92% of all patients in the Tarceva and placebo groups, respectively, had received a prior platinum-containing regimen and 36% and 37% of all patients, respectively, had received a prior taxane therapy.
93% odnosno 92% svih bolesnika u skupini koja je primala lijek Tarceva odnosno skupini koja je primala placebo, već je bilo primilo terapijski protokol s platinom, a 36% odnosno 37% svih bolesnika prethodno je bilo liječeno taksanima.
Ninety-two subjects were randomised by three age cohort strata (2:1) to eltrombopag (n=63) or placebo (n=29).
Devedeset dvoje ispitanika bilo je randomizirano prema tri stratuma dobnih kohorti (2:1) na primanje eltrombopaga (n=63) ili placeba (n=29).
Nintedanib blocks the activity of a group of proteins which are involved in the development of new blood vessels that cancer cells need to supply them with food and oxygen.
Nintedanib blokira aktivnost skupine proteina uključenih u razvoj novih krvnih žila koje su stanicama raka potrebne za opskrbu hranom i kisikom.
Nintedanib exposure increased linearly with patient age, was inversely correlated to weight, and was generally higher in patients of Asian race.
Izloženost nintedanibu linearno se povećava s dobi bolesnika, bila je obrnuto povezana s tjelesnom težinom, te je općenito bila veća u bolesnika azijske rase.
Nintedanib had no effect on the PK of pirfenidone (see section 4.4).
Nintedanib nije imao učinak na PK pirfenidona (vidjeti dio 4.4).
Nintedanib inhibits the activation of FGFR and PDGFR signalling cascades which are critically involved in proliferation, migration and differentiation of lung fibroblasts/myofibroblasts, the hallmark cells in the pathology of idiopathic pulmonary fibrosis.
Nintedanib inhibira aktivaciju FGFR i PDGFR signalnih kaskada, koje su od kritičnog značaja za proliferaciju, migraciju i diferencijaciju plućnih fibroblasta/miofibroblasta, karakterističnih stanica u patologiji idiopatske plućne fibroze.
Nintedanib is a small molecule tyrosine kinase inhibitor including the receptors platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, and VEGFR 1-3.
Nintedanib je mala molekula, inhibitor tirozin-kinaze, uključujući α i ß receptore za faktora rasta koji potječe od trombocita (engl. platelet-derived growth factor receptor, PDGFR) receptor fibroblastnog faktora rasta (engl. fibroblast growth factor receptor, FGFR) 1-3 i VEGFR 1-3.
Nintedanib is preferentially distributed in plasma with a blood to plasma ratio of 0.869.
Nintedanib je distribuiran pretežno u plazmi s omjerom krv / plazma od 0,869.
Nintedanib may cause foetal harm in humans (see section 5.3).
Nintedanib može uzrokovati fetalno oštećenje u ljudi (vidjeti dio 5.3).
Nipple disorder
poremećaj bradavice
nipple pain
bol u bradavicama
Nipple pain
bolnost bradavica
nisoldipine
verapamil
Nitisinone treatment
Liječenje nitizinonom
Nitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for > 70 % of the nitric oxide dose inhaled.
Utvrđeno je da je nitrat predominantni metabolit dušikovog (II) oksida koji se izlučuje urinom i čini > 70% udahnute doze dušikovog (II) oksida.
nitrates (for chest pain)
nitrate (za ublažavanje boli u prsima)
Nitric oxide (NO) 400 ppm mol/mol.
Dušikov (II) oksid (NO) 400 ppm mol/mol.
Nitric oxide (NO) 800 ppm mol/mol.
Dušikov (II) oksid (NO) 800 ppm mol/mol.
Nitric oxide is absorbed systemically after inhalation.
Dušikov (II) oksid apsorbira se sistemski nakon inhalacije.
Nitric oxide is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture using an approved (CE-marked) nitric oxide delivery system.
Dušikov (II) oksid isporučuje se bolesniku pomoću mehaničke ventilacije nakon razrjeđivanja mješavinom kisika/zraka putem odobrenog sustava (s CE oznakom) za dopremu dušikovog (II) oksida.
Nitric oxide is genotoxic in some test systems..
Dušikov (II) oksid genotoksičan je u nekim sustavima ispitivanja.
Nitrile gloves should be worn when handling patches and cleansing treatment areas.
Za vrijeme rukovanja flasterima i čišćenja liječenih područja treba nositi nitrilne rukavice.
Nitrofurantoin – an antibiotic used to treat urinary and kidney infections
Nitrofurantoin – antibiotik koji se koristi za liječenje mokraćne i bubrežne infekcije
Nitrogen is a building block of proteins, because of this there is a build up of nitrogen in the body after eating protein.
Budući da je dušik sastavni dio proteina, nakon uzimanja proteina kroz hranu dolazi do nakupljanja dušika u tijelu.
nitroglycerin and other nitrates, or other substances called “vasodilators”;
nitroglicerinom i drugim nitratima, ili drugim tvarima koje se nazivaju „vazodilatatori“;
nitroglycerin and other nitrates, or other substances called “vasodilators”; medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
nitroglicerin i drugi nitrati, ili drugi lijekovi koji se nazivaju „vazodilatatori“; lijekovi koji se primjenjuju za liječenje HIV infekcije/SIDA (npr. ritonavir, indinavir, nelfinavir);
Nivestim 12 MU/ 0.2 ml solution for injection/ infusion: each pre-filled syringe contains 12 million units (MU), 120 micrograms of filgrastim in 0.2 ml (corresponding to 0.6 mg/ml).
Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju: jedna napunjena štrcaljka sadrži 12 milijuna jedinica (MU), 120 mikrograma filgrastima u 0,2 ml otopine (što odgovara 0,6 mg/ml).
Nivestim 12 MU/ 0.2 ml solution for injection/infusion
Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju
Nivestim 12 MU/ 0.2 ml solution for injection/infusion Nivestim 30 MU/ 0.5 ml solution for injection/infusion Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 12 MU/ 0,2 ml otopina za injekciju/infuziju Nivestim 30 MU/ 0,5 ml otopina za injekciju/infuziju Nivestim 48 MU/ 0,5 ml otopina za injekciju/infuziju
Nivestim 12 MU/ 0.2 ml solution for injection/infusion,
Nivestim 12 MU/ 0,2 ml otopina za injekciju/infuziju
Nivestim 12 MU/0.2 ml solution for injection/infusion Filgrastim
Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju filgrastim
Nivestim 12 MU/0.2 ml solution for injection/infusion Nivestim 30 MU/0.5 ml solution for injection/infusion Nivestim 48 MU/0.5 ml solution for injection/infusion Filgrastim
Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju Nivestim 30 MU/0,5 ml otopina za injekciju/ infuziju Nivestim 48 MU/0,5 ml otopina za injekciju/ infuziju filgrastim
Nivestim 30 MU 0.5 ml solution for injection/infusion Filgrastim
Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju filgrastim
Nivestim 30 MU/ 0.5 ml solution for injection/ infusion: each pre-filled syringe contains 30 million units (MU), 300 micrograms of filgrastim in 0.5 ml (corresponding to 0.6 mg/ml).
Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju: jedna napunjena štrcaljka sadrži 30 milijuna jedinica (MU), 300 mikrograma filgrastima u 0,5 ml otopine (što odgovara 0,6 mg/ml).
Nivestim 30 MU/ 0.5 ml solution for injection/infusion
Nivestim 30 MU/ 0,5 ml otopina za injekciju/infuziju
Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 30 MU/0,5 ml otopine za injekciju/infuziju, Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju
Nivestim 48 MU/ 0.5 ml solution for injection/ infusion: each pre-filled syringe contains 48 million units (MU), 480 micrograms of filgrastim in 0.5 ml (corresponding to 0.96 mg/ml).
Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju: jedna napunjena štrcaljka sadrži 48 milijuna jedinica (MU), 480 mikrograma filgrastima u 0,5 ml otopine (što odgovara 0,96 mg/ml).
Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 48 MU/ 0,5 ml otopina za injekciju/infuziju
Nivestim 48 MU/0.5 ml solution for injection/infusion Filgrastim
Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju filgrastim
Nivestim can be used:
Nivestim se može koristiti:
Nivestim containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes.
Nivestim koji sadrži r-metHuG-CSF (filgrastim) uzrokuje izrazit porast broja neutrofila u perifernoj krvi unutar 24 sata, kao i manji porast broja monocita.
Nivestim contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially sodium-free.
Nivestim sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. u biti ne sadrži natrij.
Nivestim contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially sodium-free.
Nivestim sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
Nivestim contains no preservative.
Nivestim ne sadrži konzervans.
Nivestim contains sodium and sorbitol
Nivestim sadrži natrij i sorbitol
Nivestim is a clear colourless solution for injection/ infusion in a glass pre-filled syringe with an injection needle (stainless steel) with a needle guard.
Nivestim je bistra bezbojna otopina za injekciju/infuziju u napunjenoj staklenoj štrcaljki s iglom za injekciju (od nehrđajućeg čelika) i štitnikom za iglu.
Nivestim is a white blood cell growth factor (granulocyte colony stimulating factor) and belong to a group of medicines called cytokines.
Nivestim je faktor rasta bijelih krvnih stanica (faktor stimulacije kolonije granulocita) i pripada skupini lijekova zvanih citokini.
Nivestim is one of a group of products that stimulate the production of white blood cells.
Nivestim je jedna skupina lijekova koja stimulira stvaranje bijelih krvnih stanica.
Nivestim is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia).
Nivestim se koristi za liječenje djece koja primaju kemoterapiju ili koja trpe od teškog smanjenja broja bijelih krvnih stanica (neutropenija).
Nivestim is usually given as a daily injection into the tissue under the skin (known as a subcutaneous injection).
Nivestim se obično daje dnevnom injekcijom u tkivo ispod kože (poznata kao supkutana injekcija).
Nivestim must not be diluted with sodium chloride solution.
Nivestim se ne smije razrjeđivati s otopinom natrijeva klorida.
Nivestim must not be diluted with sodium chloride solutions.
Nivestim se ne smije razrjeđivati s otopinom natrijeva klorida.
Nivestim should not affect your ability to drive and use machines.
Nivestim ne bi smio utjecati na Vašu sposobnost upravljanja vozilima i rada sa strojevima.
Nivolumab
p<0,0001
Nivolumab 3 mg/kg (events: 183/410), median and 95% CI: 25.00 (21.75, N.A.)
Nivolumab 3 mg/kg (događaji: 183/410), medijan i 95% CI: 25,00 (21,75; ND)
Nivolumab 3 mg/kg showed an overall response rate of 14.5% (95% CI: 8.7,22.2%), a median OS of 8.21 months (95% CI: 6.05,10.9), and a median PFS of 1.87 months (95% CI 1.77,3.15).
Nivolumab u dozi od 3 mg/kg ostvario je stopu ukupnog odgovora od 14,5% (95% CI: 8,7-22,2%), medijan OS-a od 8,21 mjeseca (95% CI: 6,05-10,9) i medijan PFS-a od 1,87 mjeseci (95% CI: 1,77-3,15).
Nivolumab 3 mg/kg showed an overall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of 8.21 months (95% CI: 6.05-10.9 months ), and a median PFS of
Nivolumab u dozi od 3 mg/kg ostvario je stopu ukupnog odgovora od 14,5% (95% CI: 8,7-22,2%), medijan OS-a od 8,21 mjeseca (95% CI: 6,05-10,9 mjeseci) i medijan PFS-a od
Nivolumab attaches to a target protein called programmed death-1 receptor (PD-1) that can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body’s natural defences).
Nivolumab se vezuje za ciljni protein koji se naziva receptorom programirane stanične smrti (engl. programmed death-1 receptor, PD-1) i koji može zaustaviti aktivnost T-stanica (jedne vrste bijelih krvnih stanica koje čine dio imunosnog sustava, prirodnog obrambenog sustava tijela).
Nivolumab attaches to a target protein called programmed death-1 receptor (PD-1) that can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body’s natural defences).
Nivolumab se veže za ciljni protein koji se naziva receptorom programirane stanične smrti-1 (engl. programmed death-1 receptor, PD-1) i koji može zaustaviti aktivnost T-stanica (jedne vrste bijelih krvnih stanica koje čine dio imunosnog sustava, prirodnog obrambenog sustava tijela).
Nivolumab BMS 10 mg/mL concentrate for solution for infusion.
Nivolumab BMS 10 mg/ml koncentrat za otopinu za infuziju.
Nivolumab BMS can be used for intravenous administration either:
Nivolumab BMS se može upotrijebiti za intravensku primjenu:
Nivolumab BMS can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in the treatment of cancer.
Nivolumab BMS se izdaje samo na liječnički recept te liječenje treba započeti i provoditi liječnik s iskustvom u primjeni antitumorske terapije.
Nivolumab BMS concentrate for solution for infusion (sterile concentrate) is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles.
Nivolumab BMS koncentrat za otopinu za infuziju (sterilni koncentrat) je bistra do opalescentna, bezbojna do blijedožuta tekućina koja može sadržavati malu količinu sitnih čestica.
Nivolumab BMS concentrate may be diluted with either: sodium chloride 9 mg/mL (0.9%) solution for injection; or
Koncentrat lijeka Nivolumab BMS može se razrijediti:
Nivolumab BMS concentrate may be diluted with either: sodium chloride 9 mg/mL (0.9%) solution for injection; or
Koncentrat lijeka Nivolumab BMS može se razrijediti: otopinom natrijeva klorida za injekciju od 9 mg/ml (0,9%); ili
Nivolumab BMS have been shown to improve patients’ survival in one main study involving 272 patients with previously treated squamous NSCLC that was advanced or had spread throughout the body.
U jednom glavnom ispitivanju koje je obuhvatilo 272 bolesnika s prethodno liječenim skvamoznim NSCLC-om, koji je uznapredovao ili se proširio kroz tijelo, utvrđeno je da lijek Nivolumab BMS poboljšava preživljenje bolesnika.
Nivolumab BMS infusion
Infuzija lijeka Nivolumab BMS
Nivolumab BMS infusion should not be infused at the same time in the same intravenous line with other agents.
Nivolumab BMS se ne smije infundirati istodobno s drugim lijekovima kroz istu intravensku liniju.
Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Nivolumab BMS indiciran je za liječenje lokalno uznapredovalog ili metastatskog planocelularnog raka pluća nemalih stanica (engl. non-small cell lung cancer, NSCLC) u odraslih osoba nakon prethodne kemoterapije.
Nivolumab BMS should be continued in the presence of hormone replacement therapya as long as no symptoms are present
Liječenje lijekom Nivolumab BMS treba nastaviti uz hormonsku nadomjesnu terapijua, pod uvjetom da nema nikakvih simptoma
Nivolumab BMS should not be used in children and adolescents below 18 years of age.
Nivolumab BMS se ne smije primjenjivati u djece i adolescenata mlađih od 18 godina.
nivolumab docetaxel
nivolumab docetaksel
Nivolumab has been designed to attach to a receptor called PD-1 which is found on certain cells of the immune system called T cells.
Nivolumab je osmišljen za vezivanje na receptor naziva PD-1 koji se nalazi u određenim stanicama imunosnog sustava nazvanim T stanice.
Nivolumab in combination with ipilimumab
Nivolumab u kombinaciji s ipilimumabom
Nivolumab in combination with ipilimumab should be discontinued for life-threatening or recurrent severe cardiac and pulmonary adverse reactions.
Nivolumab u kombinaciji s ipilimumabom mora se prestati primjenjivati u slučaju po život opasnih ili rekurentnih teških srčanih i plućnih nuspojava.